Rilpivirine hydrochloride

Independent reference data for Rilpivirine hydrochloride (CAS 700361-47-3), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; Reverse Transcriptase InhibitorsRilpivirine (brand names: Edurant and Edurant PED) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for use with other HIV medicines for the treatment of HIV in adults and children 2 years of age and older who weigh at least 31 lb (14 kg) who have never taken HIV medicines before and who meet certain requirements, as determined by a health care provider.

Synonyms and trade names

Rilpivirine hydrochloride; Rilpivirine HCl; 700361-47-3; Edurant; TMC278 hydrochloride; 212WAX8KDD; EDURANT PED; Rilpivirine (as hydrochloride); TMC-278 HYDROCHLORIDE; CHEBI:68602; DTXSID80220320; EVIPLERA COMPONENT RILPIVIRINE HYDROCHLORIDE; JULUCA COMPONENT RILPIVIRINE HYDROCHLORIDE; RefChem:55981; DTXCID80142811; (E)-4-((4-((4-(2-Cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile hydrochloride

GHS hazard classification

Reported hazard statements	H302 (100%), H319 (100%)

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

What the public record says

Rilpivirine hydrochloride · CAS 700361-47-3 · C22H19ClN6. UNII 212WAX8KDD.

Source: PubChem / Wikidata; the batch COA governs where values differ.